NASDAQ:APLT Applied Therapeutics Q2 2024 Earnings Report $0.47 +0.03 (+7.36%) Closing price 04:00 PM EasternExtended Trading$0.47 0.00 (-0.19%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Applied Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.10Beat/MissMissed by -$0.03One Year Ago EPSN/AApplied Therapeutics Revenue ResultsActual Revenue$0.14 millionExpected Revenue$10.00 millionBeat/MissMissed by -$9.86 millionYoY Revenue GrowthN/AApplied Therapeutics Announcement DetailsQuarterQ2 2024Date8/7/2024TimeN/AConference Call DateWednesday, August 7, 2024Conference Call Time7:00AM ETUpcoming EarningsApplied Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Monday, August 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Applied Therapeutics Earnings HeadlinesApplied Therapeutics, Inc. (APLT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comApplied Therapeutics Announces Key Leadership AppointmentsJune 17, 2025 | globenewswire.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.July 17 at 2:00 AM | Golden Portfolio (Ad)Applied announces INSPIRE Phase 2/3 trial primary endpoint not significantMay 18, 2025 | msn.comApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 18, 2025 | globenewswire.comApplied Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comSee More Applied Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email. Email Address About Applied TherapeuticsApplied Therapeutics (NASDAQ:APLT) is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapeutics that address the underlying causes of serious diseases. The company’s research focuses on metabolic and renal indications, aiming to bring differentiated treatments to patients with high unmet medical needs. Applied Therapeutics leverages a deep understanding of human biology and a precision medicine approach to identify targets that can modulate disease pathways and deliver meaningful clinical benefits. The company’s most advanced program targets mitochondrial dysfunction and impaired energy metabolism with its investigational small molecule, beraprost sodium. Initially developed as a prostacyclin analogue, beraprost is being repositioned by Applied Therapeutics to explore new indications in rare metabolic disorders and chronic kidney disease. In addition to beraprost, the company’s pipeline includes small molecules designed to restore cellular homeostasis by enhancing nicotinamide adenine dinucleotide (NAD+) levels. These programs are supported by preclinical and early‐stage clinical studies that aim to validate mechanisms of action and demonstrate safety and efficacy in targeted patient populations. Applied Therapeutics was founded in 2018 and is headquartered in New York City. Since its inception, the company has built a specialized team of drug discovery scientists, clinical development experts, and regulatory professionals. Applied Therapeutics collaborates with academic institutions and biotech partners to accelerate the translation of its research into clinical milestones. The company’s strategic alliances and in-licensing agreements have expanded its capabilities in medicinal chemistry, preclinical toxicology, and clinical trial execution. Under the leadership of President and Chief Executive Officer James (“Jim”) McArthur, Applied Therapeutics has advanced from an early research outfit to a publicly traded biotech firm listed on the Nasdaq exchange. The management team includes seasoned executives with prior experience at leading pharmaceutical and biotechnology companies, providing strong governance and operational expertise. As Applied Therapeutics progresses its clinical programs, the company remains committed to delivering innovative therapies that improve patient outcomes in metabolic and renal diseases worldwide.Written by Jeffrey Neal JohnsonView Applied Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Citigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting Cycle Upcoming Earnings American Express (7/18/2025)HDFC Bank (7/18/2025)3M (7/18/2025)Southern Copper (7/18/2025)Charles Schwab (7/18/2025)Truist Financial (7/18/2025)NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.